Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo.
Therapeutic and diagnostic applications have been envisioned for aptamers, a class of oligonucleotide ligands that bind their target molecules with high affinity and specificity (Gold, J. Biol. Chem. 270, 13581-13584, 1995). To identify parameters that are important for the in vivo activity of aptamers acting on intravascular targets, we have studied binding characteristics in vitro, pharmacokinetic parameters in Sprague-Dawley rats, and inhibitory activity in a SCID mouse/human lymphocyte model of lymphocyte trafficking for both 2'F pyrimidine 2'OH purine RNA and ssDNA anti-human L-selectin aptamers. The data indicate that aptamers with low nanomolar affinity are suitable candidates for use as in vivo reagents and that nonspecific binding to vascular cells is not an issue for efficacy. As is often observed for other reagents, plasma clearance is biphasic. Both the distribution phase and the clearance rate strongly affect in vivo activity. Pharmacokinetic parameters and in vivo activity are significantly improved by conjugating aptamers to a carrier molecule, such as polyethylene glycol (PEG). Most active in vivo is 1d40, a 2'F pyrimidine 2'OH purine aptamer conjugated to 40 kDa PEG. At a dose of 5.4 nmol/kg body weight, its duration of effect (time to 50% inhibition) is 11.2 hours, and at 1 mg or 90 nmol/kg, its plasma clearance rate (CL) is 0.4 ml/min/kg. Its ED50 is estimated to be 80 pmol/kg in preinjection dose-response experiments, compared with 4 pmol/kg for the dimeric anti-L-selectin antibody DREG56. Further improvement of in vivo activity is expected from nucleotide modifications that increase resistance to nuclease digestion for aptamers where mass is not rate limiting for clearance. Because the relationship of clearance to conjugate molecular weight (MW) is not the same for all aptamers, it is advisable to determine the relationship at the outset of in vivo studies. In summary, the data suggest that properly formulated aptamers have the capacity to be effective therapeutic agents against intravascular targets.
Watson
S R
SR
NeXstar Pharmaceuticals, Inc., Boulder, CO 80301, USA.
Chang
Y F
YF
O'Connell
D
D
Weigand
L
L
Ringquist
S
S
Parma
D H
DH
D000818:Animals; D001667:Binding, Competitive; D002465:Cell Movement / Q000276:immunology; D004277:DNA, Single-Stranded / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D019041:L-Selectin / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D008024:Ligands; D008198:Lymph Nodes / Q000166:cytology / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism; D051379:Mice; D016513:Mice, SCID; D008970:Molecular Weight; D009690:Nucleic Acid Conformation; D009841:Oligonucleotides / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley
D004277:DNA, Single-Stranded; D008024:Ligands; D009841:Oligonucleotides; D019041:L-Selectin